Ultomiris is a medication developed by Alexion Pharmaceuticals, Inc. to manage and mitigate the occurrence and morbidity associated with meningococcal infections. It is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), which requires healthcare providers to be specifically certified and follow certain program requirements.
The ULTOMIRIS REMS program includes steps for healthcare providers to review educational materials, enroll in the program, and counsel patients using patient safety brochures and cards. Adverse events, including reports of meningococcal infection, should be reported to Alexion Pharmaceuticals, Inc. or the FDA MedWatch Reporting System. Ultomiris is a registered trademark of Alexion Pharmaceuticals, Inc.
Generated from the website